Objectives- To compare the efficacy of oral propranolol, Prednisolone and propanolol with prednisolone in the treatment of infantile hemangiomas and to standardise the dose of propranolol. Design - Prospective randomized comparative study. Setting - Pediatrics Surgery Department of a Tertiary care hospital. Study period - September 2012 to December 2014. Participants - Infants below 8 months of age with cosmetically disfiguring or functionally deranging hemangiomas. Results - The mean size reduction (%) based on visual Analogue scale for propranolol treated group at 3 months, 6 months, 1 year, and 1.5 years were 58.21+19.50, 71.21+18.35, 85+11.32 and 89.883+10.26 respectively. For the group treated with prednisolone at the same period the size reduction was 36.57+18.97, 46.94+26.84, 66.25+31.21 and 66.64+32.36 respectively. For the group treated with Prednisolone and Propranolol the reduction the above age were 49.99+19.25, 71.07+17.69, 79.19+13.95 and 82.64+10.36 respectively. The side effects are more with prednisolone group and prednisolone with prepranolol group. Conclusion - Propranolol should be considered as first line agent in therapy for infantile hemangioma for its safety and efficacy. 2 mg/kg/day in two divided doses considered to be optimal.
No takes yet. Share an insight, caveat, or question.
Sarangi et al. (2018) studied this question.